Study drug for active eye inflammation
Treatments studied
Part of Eyes & vision clinical trials.
This trial tests a new drug called tulisokibart for people with active inflammation in the back of the eye (uveitis). The drug may help reduce inflammation and prevent vision loss.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have active inflammation in the middle or back part of the eye (uveitis) in at least one eye.
- You must be on a stable dose of any immunosuppressive or steroid eye medications before starting the trial.
- You cannot have inflammation only in the front of the eye.
- You cannot have certain other eye conditions or past surgeries that might interfere with the trial.
- You must be free of active infections or recent cancer.
- You must not have had a bad reaction to high-dose steroids in the past.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug (GenSci048) for people with active, non-infectious uveitis in the middle or back of the eye, who are already taking oral steroids. The goal is to see if the drug can better control inflammation and reduce the need for steroids.
This trial tests a new drug called FXS5626 to treat non-infectious uveitis—inflammation inside the eye that doesn't come from infection. The study looks at whether this drug can reduce eye inflammation and improve vision in people whose condition isn't controlled with steroid eye drops and oral steroids alone.
This trial tests a new eye drop (tacrolimus) to treat non-infectious anterior uveitis, an inflammation in the front part of the eye. It may help reduce the need for steroid eye drops.
This study follows people with non-infectious uveitis (inflammation inside the eye) that affects the middle or back of the eye. It aims to understand the disease better and see how different treatments work, which may help improve future care.
This study tests a pill called baricitinib (Olumiant) for people with uveitis (inflammation inside the eye) that hasn't improved with other biologic treatments. It aims to reduce inflammation and improve symptoms.
This study compares two biologic medicines, adalimumab and tocilizumab, to see which works better for severe eye inflammation (uveitis) caused by Behçet's disease. Both are given as injections, and the goal is to improve vision and reduce eye damage.
Hear when a new Noninfectious Intermediate, Posterior, or Panuveitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.